

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 January 2006 (12.01.2006)

PCT

(10) International Publication Number  
**WO 2006/002698 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/22**,  
A61P 3/00

PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,  
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,  
YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/EP2005/003557

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 5 April 2005 (05.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
RM2004A000327 1 July 2004 (01.07.2004) IT

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designation US

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*):  
**SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.** [IT/IT]; Viale Shakesepare, 47, I-00144 Rome (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CALVANI, Menotti** [IT/IT]; Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina KM 30,400, I-00040 Pomezia (IT).  
**AMATO, Antonino** [IT/IT]; Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina KM. 30,400, I-00040 Pomezia Rome (IT).

(74) Agent: **CAMPANELLI, Domenico**; Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina KM. 30,400, I-00040 Pomezia (IT).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,

(54) Title: USE OF ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF NEUROPATHIC PAIN IN DIABETIC PATIENTS

(57) Abstract: The use of acetyl L-carnitine, or one of its pharmaceutically acceptable salts, is described for the treatment of neuropathic pain in patients with type 2 diabetes not treated with insulin.



WO 2006/002698 A1

**Use of acetyl L-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients**

The invention described herein relates to the use of acetyl L-carnitine for the preparation of a medicine for the treatment of  
5 neuropathic pain in patients with type 2 diabetes not on insulin treatment.

Diabetic neuropathy is the most frequent peripheral neuropathy in the western world and includes different forms of neuropathy, among which diabetic polyneuropathy is the most  
10 common. The anatomico-pathological picture of diabetic neuropathy consists in a focal or diffuse aspecific loss of fibres, with demyelination associated with structural or intraneuronal abnormalities of the connective tissue or of the small vessels.

The causes of diabetic neuropathy are not known. Metabolic  
15 disequilibrium secondary to hyperglycaemia and ischaemia of the "vasa nervorum" are the best known pathogenetic mechanisms.

Various metabolic abnormalities and biochemical modifications have been documented both in experimental models of diabetes and in diabetic patients, including an increase in glucose  
20 metabolism and a reduction in myoinositol.

The characteristic symptoms of diabetic polyneuropathy consist in the presence of lancinating or burning pain accompanied by clinical signs of symmetrical impairment of sensitivity, motility and/or deep tendon reflexes; these symptoms are predominant in  
25 the distal segments of the lower limbs.

To date the therapeutic approach adopted by investigators to the use of acetyl L-carnitine for the treatment of neuropathic pain in patients with diabetes has failed to take account of the selection of patients on the basis of the type of diabetes and the type of  
5 antidiabetic agents taken up to the time of entry into clinical trials.

In fact, in the *Journal of the American Diabetes Association* June 2002, Vol. 51, Suppl., a multicentre clinical trial to assess the effect of acetyl L-carnitine treatment on neuropathy patients with type I and type 2 diabetes is described.

10 The results obtained in this trial are contradictory, showing improvements in one group but not in the other. At the end of the trial, the authors report that in the patient group recruited in Europe there was no improvement in pain symptoms, whereas an improvement was registered in the American and Canadian group.

15 The authors suggest that greater improvements were obtained in the group of type 2 diabetic patients with obesity.

In this study, too, the authors (two of whom are the inventors in the present patent application) failed to understand at the end of the trial they had conducted that a different selection of the patients  
20 to be recruited would have led to different, better and less variable results.

Moreover, a different patient selection would have avoided non-responders being included in the trial and treated with a compound which was of no use to them, i.e. ineffective, thus

subjecting these patients to the risk of incurring side effects without receiving any therapeutic benefit.

In this case, thanks to the well-known lack of severe side effects of the study compound used, the non-responders were not  
5 harmed by the drug, but the same could not be said if the study compound had been another drug, associated with more serious side effects.

Thus, in this trial, the patients were not selected on the basis of the type of therapy they had received to control their  
10 hyperglycaemia and therefore it was not understood what the cause of the improvement in one group and the lack of improvement in the other group were due to.

A report published in "*Giornale Italiano di Diabetologia*, 1998, Vol.18, pp. 30-31, abs" describes the effect of acetyl L-carnitine  
15 treatment on NIDDM diabetic patients, suffering from sensorimotor polyneuropathy.

The authors report that the results obtained in this study show an improvement in symptoms.

In this study, too, the patients were not selected on the basis  
20 of the type of therapy they had received to control their hyperglycaemia up to the time of entry into the clinical trial.. Therefore, in this case, too, it is impossible to establish whether or not a different patient selection might have led to different experimental results.

In fact, the authors suggest that only further clinical trials of longer duration would be able to demonstrate the efficacy of acetyl L-carnitine in diabetic peripheral neuropathy.

As will be explained more clearly here below, the authors were  
5 wrong: it was not by increasing the number of patients recruited into the clinical trial that the investigators would have been able to understand whether or not the study compound was active in the treatment of diabetic peripheral neuropathy; these objectives would have been achievable only through a different selection of the  
10 patients to be included in the clinical trial.

A report published in *Drugs in Research and Development* 2002, Vol. 3 (4), pp. 223-31, 2002 describes a clinical trial in which type I and II diabetics with symmetrical distal polyneuropathy or multineuropathy were recruited.

15 The results obtained in this clinical trial show that 39% of patients treated with acetyl L-carnitine out of 333 recruited presented an improvement in pain symptoms.

In this study, too, the patients were not selected on the basis of the type of therapy they had received to control their  
20 hyperglycaemia, and therefore in this case, too, it was impossible to understand what the cause of the improvement was or in what particular patient subgroup this compound is active and in what patient subgroup it is ineffective.

A report published in *Diabetologia* 1995, Vol/ISS/ p. 38/1  
25 (123) describes the effect of treatment with acetyl L-carnitine on

diabetic patients with diabetic peripheral neuropathy treated with insulin or with oral antidiabetic agents.

The results obtained in this trial show an improvement in the symptoms.

5 In this study, too, the patients were not selected on the basis of the type of diabetes or the type of therapy they had received to control their hyperglycaemia, and therefore in this case, too, it was impossible to understand what the cause of the improvement was or in what particular patient subgroup this compound is active and in  
10 what patient subgroup it is ineffective.

In fact, the authors suggest that only further clinical trials of longer duration would be able to demonstrate the efficacy of acetyl L-carnitine in diabetic peripheral neuropathy.

As already mentioned, the authors were wrong: it was not by  
15 increasing the number of patients recruited into the clinical trial that the investigators would have been able to understand whether or not the study compound was active in the treatment of diabetic peripheral neuropathy; these objectives would have been achievable only through a different selection of the patients to be included in  
20 the clinical trial.

In an article in "*Il giornale dei congressi medici*, 5, 14-19,1993" the author states that in a clinical trial 120 patients with diabetic neuropathy showed a distinct improvement in symptoms after treatment with acetyl L-carnitine.

The author of this article is one of the inventors in this patent application, and at the time he was commenting on, or became aware of, this clinical trial he had not understood that a different selection of the patients to be recruited would have led to better  
5 results than those obtained.

In fact, the author does not mention whether the patients were suffering from type I or type 2 diabetes.

In this case, too, better patient selection would have made it possible to exclude non-responders, which would have avoided them  
10 having to take a drug which for them was useless, ineffective and potentially damaging. As already mentioned, thanks to the well-known lack of severe side effects of the study compound, the non-responders were not harmed by taking the drug, but the same could not be said if the study compound was another drug, associated  
15 with more serious side effects.

Thus, in this study, too, the patients were not selected on the basis of the type of diabetes they were suffering from and therefore it was impossible to understand what subgroup of patients obtained improvement from treatment with acetyl L-carnitine.

20 In the abstracts of the National Congress of the Italian Society of Nephrophysiology, Perugia 1-4 June, 1994, p. 98, one report describes the effect of treatment with acetyl L-carnitine on diabetic patients treated with insulin or with oral antidiabetic agents, suffering from diabetic peripheral neuropathy.

The results obtained in this study show an improvement in symptoms, and the authors suggest that the improvement in the pain component in the treated group should be considered with great caution, amongst other things owing to the fact that it cannot  
5 be “weighed” precisely and they go so far as to advance complicated hypotheses of activity at nerve fibre level.

In this study, too, the patients were not selected on the basis of the type of diabetes they were suffering from and the type of therapy they had received to control their hyperglycaemia and  
10 therefore in this case, too, it was impossible to understand what subgroup of patients obtained improvement.

A report in *Clin. Drug. Invest.*, Vol. 10 (6), pp. 317-22 1995, describes the effect of acetyl L-carnitine treatment on 426 patients with peripheral neuropathy of different origins, including  
15 patients with diabetic neuropathy (13.1% of the entire study population). No information is provided regarding the type of diabetes or the type of treatment the patients had received to control their hyperglycaemia.

The results obtained in this study show an improvement in  
20 pain symptoms and the authors suggest that further studies in individual well-matched subgroups of neuropathic patients should be carried out because in their experimental model the groups were not large enough, and the treatment period not long enough for analysis to be undertaken.



As already mentioned, in this study, too, the authors were wrong: it was not by increasing the number of patients recruited into the clinical trial that the investigators would have been able to understand whether or not the study compound was active in the  
5 treatment of diabetic peripheral neuropathy.

Thus, in this study, too, the patients were not selected on the basis of the type of diabetes they were suffering from and the type of therapy they had received to control their hyperglycaemia and therefore in this case, too, it was impossible to understand what the  
10 cause of the improvement was and in what subgroup of patients it occurred.

A report in the *Journal of the Neurological Sciences*, 1997, Supp. to Vol. 150, describes the effect of acetyl L-carnitine treatment on patients with polyneuropathy.

15 In this study no information is provided regarding the type of diabetes and the type of treatment the patients had received to control their hyperglycaemia.

The results obtained in this study show an improvement in objective signs of peripheral neuropathy and in the nerve conduction  
20 velocity.

Thus, in this study, too, the patients were not selected on the basis of the type of diabetes they were suffering from and the type of therapy they had received to control their hyperglycaemia and therefore in this case, too, it was impossible to understand which  
25 specific subgroup was the responder group.

In the abstracts of the IX National Congress of the Italian Society of Clinical Pharmacology - II Congress of the Mediterranean Society of Clinical Pharmacology "Therapeutic Advances and New Health Problems", Venice, 8-10/10/1991 ABS one report describes  
5 the effect of acetyl L-carnitine treatment on 500 patients with peripheral neuropathy of different origins. No information is provided regarding the type of diabetes or the type of treatment the diabetic patients had received to control their hyperglycaemia.

The results obtained in this study show an improvement in  
10 symptoms.

In this study, too, the patients were not selected on the basis of the type of diabetes they were suffering from and the type of therapy they had received to control their hyperglycaemia and therefore in this case, too, it was impossible to understand what the  
15 cause of the improvement was and in what subgroup of patients it occurred.

The authors suggest that further studies should be carried out in larger patient groups.

As already mentioned, in this case, too, the authors were  
20 wrong: it was not by increasing the number of patients recruited into the clinical trial that the investigators would have been able to understand whether or not the study compound was active in the treatment of diabetic peripheral neuropathy; these objectives would have been achievable only through a different selection of the  
25 patients to be included in the clinical trial.

The results obtained in the clinical trials cited above, which at times are contradictory and at times present no apparent contradictions, show a number of improvements in the treated groups compared to the control groups. In these studies the patients  
5 were not selected on the basis of the type of diabetes or the type of therapy they had received up to the time of their entry into the clinical trial.

In other words, the authors of these studies did not pose the problem as to whether, within the patient population recruited there  
10 might be a group of responders and a group of non-responders because they were not aware that different patient selection would have led to better and less variable results.

The result of the lack of patient selection with different inclusion criteria from those adopted was that the authors were  
15 unable to understand the reason why there were improvements in certain cases and not in others. For this reason, the authors endowed with greater critical sense declared that it was only by increasing the number of patients and the duration of the studies that it would be possible to demonstrate (without any residual  
20 doubts) whether the study compound was active or not. The present invention demonstrates that these authors were wrong, because it was not by increasing the size of the study population or the length of the treatment periods, using the same inclusion criteria, that it would be possible to demonstrate that acetyl L-carnitine is active for  
25 the treatment of diabetic neuropathy in the patients recruited and

treated. These objectives would be achievable only by adopting different inclusion criteria.

Previous uses of acetyl L-carnitine are already known.

For example, US Patent 4,751,242 describes the use of acetyl  
5 L-carnitine for the treatment of peripheral neuropathies, of various origins, including diabetic neuropathy.

In this patent, no information is provided regarding the type of diabetes or the type of treatment the patients had received to control their hyperglycaemia.

10 In this patent, there is no description or suggestion to the effect that a different patient inclusion criterion would have yielded better therapeutic results. In fact, a different selection of patients would have avoided non-responders being included in the study and treated with a compound which was of no use to them, i.e.  
15 ineffective, thus exposing these patients to the risk of incurring side effects without receiving any therapeutic benefit.

As already mentioned, in this case, thanks to the well-known lack of severe side effects of the study compound used, non-responders were not harmed by the drug, but the same could not be  
20 said if the study compound had been another drug, associated with more serious side effects.

Thus, in this study, too, patients were not selected on the basis of the type of therapy they had received to control their hyperglycaemia, and therefore it was impossible to understand in  
25 what group of treated patients the improvement occurred.

Further uses of acetyl L-carnitine are equally well known.

US Patent 5192805 relates to the use of acetyl L-carnitine in the therapeutic treatment of coma.

US 6,037,372 relates to the use of acetyl L-carnitine, isovaleryl L-carnitine and propionyl L-carnitine for increasing IGF-1 levels, for the treatment of lateral amyotrophic sclerosis, optic and olfactory nerve neuropathies, trigeminal nerve neuralgia and other pathologies.

US 6037372 relates to the use of an alkanoyl L-carnitine, including acetyl L-carnitine, for the treatment of diseases mediated by glutamate, such as epilepsy, schizophrenia, chronic fatigue syndrome, lateral amyotrophic sclerosis and other pathologies.

It has now been found that acetyl L-carnitine lends itself to use as an effective agent for the treatment of neuropathic pain in patients with type 2 diabetes not treated with insulin.

As already mentioned, the use of acetyl L-carnitine for the treatment of neuropathies is already known. What is still unknown today at the time of filing the present application is that acetyl L-carnitine is useful for treating diabetic neuropathies in patients with type 2 diabetes non on insulin treatment.

To date, in the clinical trials in which acetyl L-carnitine has been used for the treatment of peripheral neuropathy in diabetic patients, no distinction has been made between the various types of diabetes and the various types of pharmacological treatment the diabetic patients had received.

This lack of appropriate patient selection entailed the treating of patients who (as will be demonstrated in the experimental part here below) failed to respond to treatment with acetyl L-carnitine, and very variable experimental results were obtained which did not  
5 guarantee the complete efficacy of the study compound.

In fact, in *Drugs* 1997 Sept: 54 (3) 414-421 it is reported that:

- 1) the efficacy of acetyl L-carnitine is poor;
- 2) in the context of the drugs proposed for the treatment of peripheral neuropathy, to date (September 1997) there are no  
10 data or clinical trials justifying their use in diabetic patients;
- 3) a recent clinical trial conducted in Italy in approximately 200 patients with diabetic neuropathy has failed to show any significant difference between acetyl L-carnitine and placebo (Sigma-Tau Pharmaceuticals, unpublished data protocol  
15 No. DRN 2003289I/ALC-ST200);
- 4) as of today, there are no drugs useful for the treatment of diabetic neuropathy owing to (a) the poor methodological quality of most of the trials conducted to date; (b) insufficient trial duration; (c) methodological difficulties related to the  
20 patient inclusion and exclusion criteria;
- 5) future clinical trials will have to take these problems into account.

The expert in the field knows that from the date of publication of *Drugs* 1997 Sept. 54 (3) 414-421 to today there have been no  
25 changes in the patient inclusion criteria, and therefore the

difficulties encountered in interpreting the results have remained the same.

Thanks to the present invention we now know that a different method of selecting the patients to be included in clinical trials, and  
5 therefore treated, would have demonstrated the efficacy of the study compound without leaving any residual doubts regarding the interpretation of the results (see the experimental part here below).

The subject of the present invention is therefore the use of acetyl L-carnitine, or one of its pharmaceutically acceptable salts, for  
10 the preparation of a medicine for the treatment of neuropathic pain in patients with type 2 diabetes not treated with insulin.

What is meant by pharmaceutically acceptable salt of acetyl L-carnitine is any salt of the latter with an acid that does not give rise to unwanted toxic or side effects. These acids are well known to  
15 experts in pharmaceutical technology.

Examples of such salts, though not exclusively the following, are: chloride, bromide, orotate, acid aspartate, acid citrate, magnesium citrate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, mucate, acid oxalate,  
20 pamoate, acid pamoate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino-ethane sulphonate, magnesium 2-amino-ethane sulphonate, choline tartrate and trichloroacetate.

The following examples illustrate the invention.

25 **EXAMPLE 1**

Two double-blind placebo-controlled clinical trials, identical in their experimental design, were conducted in patients with diagnoses of diabetic peripheral neuropathy selected according to the criteria established in the San Antonio, Texas conference  
5 (*Diabetes* 37:1000-1004, 1988).

Acetyl L-carnitine was administered orally at doses of 1.5 g/day and 3.0 g/day for continuously for 52 weeks.

One objective of the studies consisted in the possible modification of the Visual Analogue Scale (VAS) (Scott J. Huskisson  
10 EC. Graphic representation of pain. *Pain* 1976;2:175-184) in the subjective assessment of pain symptoms and the main sensorimotor clinical parameters.

Two populations of patients with type 2 diabetes were treated, the first of which comprised patients not treated with  
15 insulin; this population included the presence of a control group of patients who did not receive the study compound (placebo, Group 1) and who matched up to the same inclusion criteria as the patients treated with acetyl L-carnitine (not on insulin treatment).

The second population comprised patients with type 2  
20 diabetes treated with insulin. Here, too, the population included a placebo group (Group 4) matching up to the same inclusion criteria as the patients treated with acetyl L-carnitine (on insulin treatment).

The overall results obtained in the patients of the two studies  
25 are presented in Tables 1 and 2.



**Table 1**Patients with type 2 diabetes not on insulin treatment

<b>Group</b>	<b>Treatment</b>	<b>Results</b>	
		<b>VAS</b>	<b>"P value" vs. placebo</b>
1	Placebo (n = 28 pts)	3.4 ± 23.3	-
2	Acetyl L-carnitine 1.5 g/day (n = 39 pts)	7.6 ± 34.7	<i>P</i> = N.S.
3	Acetyl L-carnitine 3.0 g/day (n=40 pts)	24.2 ± 32.3	<i>P</i> = 0-006

5

**Table 2**Patients with type 2 diabetes on insulin treatment

<b>Group</b>	<b>Treatment</b>	<b>Results</b>	
		<b>VAS</b>	<b>"P value" vs. placebo</b>
4	Placebo (n = 58 pts)	14.2 ± 32.2	-
5	Acetyl L-carnitine 1.5 g/die (n = 41 pts)	16.8 ± 30.1	<i>P</i> = N.S.
6	Acetyl L-carnitine 3.0 g/day (n = 57 pts)	25.9 ± 31.2	<i>P</i> = N.S.

The results reported in Table 1 show that, at the end of treatment in patients with type 2 diabetes not on insulin treatment, acetyl L-carnitine was active in a dose-related manner, i.e. only at the higher dose (3 g/day), compared to the placebo group.

10

In contrast, the results reported in Table 2 show that the same compound, used in patients with type 2 diabetes on insulin treatment, showed no statistically significant difference in activity, even at the higher dose, compared to the control group.

5           It is interesting to note in Table 2 that the placebo group and the patient group treated with the lower dose of acetyl L-carnitine (1.5 g/day) present higher VAS scores, at the end of treatment, than the equivalent groups in Table 1; it is believed that this difference may be attributable to the effect of the insulin treatment, which is  
10 no longer detectable at the higher dose of the study compound.

          If the study compound had also been active in the type 2 diabetic patients on insulin treatment, the difference in activity vs. the placebo group (Group 4) and the group receiving acetyl L-carnitine at the lower dose (Group 5) should have been maintained  
15 in that population.

          The results presented in Tables 1 and 2 are the demonstration that the clinical trials carried out in the past, which did not envisage patient selection according to the principles outlined in the present invention, showed signs of activity which  
20 were not to be regarded as predictive of real activity in the entire population treated, but were simply casual positive responses, without the investigators understanding the real reason for them. These responses were caused in part by the real clinical improvement in a number of patients and by the placebo effect in  
25 the others.

Acetyl L-carnitine is a known compound, whose preparation procedure is described in US patents US 4439438 and US 4254053.

The acetyl L-carnitine can be in any form suitable for oral or parenteral administration in human subjects.

5           On the basis of various factors, such as the concentration of the active ingredient or the patient's condition, the compound according to the invention can be marketed as a food supplement or nutritional supplement, or as a therapeutic product on sale either with or without a compulsory doctor's prescription.

10           It has been found that, although the daily dose of the above-mentioned active ingredient to be administered depends on the patient's age, weight and general condition, using professional experience, it is generally advisable to administer, whether as a single dose or in multiple doses, approximately 1.5 to 5 g/day of  
15 acetyl L-carnitine, or an equimolar amount of one of its pharmaceutically acceptable salts. The preferred doses are greater than 1.5 g/day and may be as much as the maximum dose advised, thanks to the extremely low toxicity of said active ingredient.

          The medicine according to the present invention can be  
20 prepared by mixing the active ingredient (acetyl L-carnitine inner salt or one of its pharmaceutically acceptable salts) with suitable excipients for the formulation of compositions for enteral administration (particularly oral administration) or for parenteral administration (particularly via the intramuscular or intravenous  
25 routes).

Experts in pharmaceutical technology are familiar with said excipients.

The pharmaceutically acceptable salts of the above-mentioned active ingredients include all the pharmaceutically acceptable salts  
5 which are prepared by addition of an acid to acetyl L-carnitine inner salt, and which do not give rise to unwanted toxic or side effects. The formation of salts by addition of an acid is well known in pharmaceutical technology.

**CLAIMS**

1. Use of acetyl L-carnitine, or one of its pharmaceutically acceptable salts, for the preparation of a medicine for the treatment of neuropathic pain in patients with type 2 diabetes not treated with insulin.
2. Use according to claim 1, in which the pharmaceutically acceptable salt of acetyl L-carnitine is selected from the group consisting of chloride, bromide, orotate, acid aspartate, acid citrate, magnesium citrate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, mucate, acid oxalate, pamoate, acid pamoate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-amino-ethane sulphonate, magnesium 2-amino-ethane sulphonate, choline tartrate and trichloroacetate.
3. Use according to claim 1, in which acetyl L-carnitine is administered orally at a dose greater than 1.5 g/day.
4. Use according to claim 1 in which acetyl L-carnitine is administered orally at a dose of 3 g/day.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/003557

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/22 A61P3/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBASE, BIOSIS, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRANDIS ET AL: "Acetyl-L-Carnitine (Levacecarnine) in the Treatment of Diabetic Neuropathy" DRUGS R&D, vol. 3, no. 4, 2002, - 2002 pages 223-231, XP001206970 see "Study participants" and "Efficacy" page 227, left col.	1-4
X	GRANDIS: "Tolerability and efficacy of L Acetylcarnitine in Patients with Peiferal neuropathies" CLIN.DRUG.INVEST, vol. 15, no. 2, 1998, - 1998 pages 73-79, XP001106152 See "Table 1" and "Pain Reduction". ----- -/-	1-4

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 July 2005

Date of mailing of the international search report

11/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cattell, James

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/003557

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 751 242 A (CALVANI ET AL) 14 June 1988 (1988-06-14) column 3, lines 13-34 -----	1-4

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/003557

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4751242 A	14-06-1988	IT 1196564 B	16-11-1988
		AT 70439 T	15-01-1992
		CA 1298197 C	31-03-1992
		DE 3775301 D1	30-01-1992
		DK 403587 A ,B,	05-02-1988
		EP 0256999 A2	24-02-1988
		ES 2039262 T3	16-09-1993
		GR 3003405 T3	17-02-1993
		JP 2093191 C	18-09-1996
		JP 8005786 B	24-01-1996
		JP 63044522 A	25-02-1988
		ZA 8705643 A	30-11-1988